Lapatinib ditasylate
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071748
CAS NO.388082-77-7
Purity 95%
MDL NumberMFCD09264195
Molecular FormulaC29H26ClFN4O4S.2C7H8O3S
Molecular Weight925.472
Melting point: 240~242°C
| Category | Content |
|---|---|
| Generic Name | Lapatinib Ditosylate Monohydrate |
| Chemical Formula | C43H44ClFN4O11S3 |
| CAS Number | 388082-78-8 |
| Mechanism of Action | Lapatinib Ditosylate Monohydrate is a dual inhibitor of EGFR and ErbB-2 tyrosine kinases, with IC50 values of 10.8 nM and 9.2 nM, respectively. It induces cell cycle arrest in the G1 phase and inhibits tumor growth. |
| Indications | – Used for the treatment of advanced breast cancer.<br>- Investigated for other solid tumors. |
| Dosage Forms | Oral tablets. |
| Administration | – Usual dose: 1250 mg orally once daily.<br>- Take with or without food. |
| Common Side Effects | – Diarrhea.<br>- Nausea.<br>- Vomiting.<br>- Fatigue.<br>- Rash.<br>- Dry skin.<br>- Hair loss.<br>- Nausea.<br>- Stomach discomfort. |
| Serious Side Effects | – Liver toxicity.<br>- Cardiotoxicity.<br>- Interstitial lung disease.<br>- Severe allergic reactions.<br>- Skin reactions (e.g., rash, loosening of nails).<br>- Swelling of the face, feet, or lower legs.<br>- Yellowing of the skin or eyes. |
| Storage Conditions | Store at -25 to -15°C. |
| Developer | GlaxoSmithKline (GSK) |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
